References
- Bacchi, C. L. (1999). Women, policy and politics. London: Sage.
- Begley, A., & Coveney, J. (2010). Wonder vitamin or mass medication? Media and academic representation of folate fortification as a policy problem in Australia and New Zealand. Australian and New Zealand Journal of Public Health, 34, 466–471.10.1111/azph.2010.34.issue-5
- Braun, V., & Clarke, V. (2012). Chapter 4: Thematic analysis. In H. Cooper (Ed.), APA handbook of research methods in psychology: Volume 2. Research designs. (pp. 57–71). Washington, DC: American Psychological Association.
- CSDH. (2008). Closing the gap in a generation: Health equity through action on the social determinants of health. Final report of the Commission on Social Determinants of Health. Geneva: World Health Organization.
- Dourado, E., & Robinson, I. (2014). How many jobs does intellectual property create? Arlington, VA: Mercatus Center, George Mason University.
- Faunce, T. A., & Townsend, R. (2010). Public health and medicine policies. In J. Kelsey (Ed.), No ordinary deal: Unmasking the Trans-Pacific Partnership free trade agreement (pp. 149–162). Crows Nest: Allen & Unwin.10.7810/9781877242502
- Faunce, T. A., & Townsend, R. (2011). The Trans-Pacific Partnership Agreement: Challenges for Australian health and medical policies. Medical Journal of Australia, 194, 83–86.
- Gleeson, D., Lopert, R., & Reid, P. (2013). How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand. Health Policy, 112, 227–233.10.1016/j.healthpol.2013.07.021
- Government Accountability Office. (2006). New drug development: Science, business, regulatory and intellectual property issues cited as hampering drug development efforts. GAO-07-49. Retrieved December 31, 2013, from http://www.gao.gov/new.items/d0749.pdf
- Hollis, A. (2004). Me-too drugs: Is there a problem? Retrieved January 24, 2014, from http://www.who.int/intellectualproperty/topics/ip/Me-tooDrugs_Hollis1.pdf
- Jatrana, S., Crampton, P., & Norris, P. (2011). Ethnic differences in access to prescription medication because of cost in New Zealand. Journal of Epidemiology & Community Health, 65, 454–460.
- Kemp, A., Glover, J., Preen, D. B., Bulsara, M., Semmens, J., & Roughead, E. E. (2013). From the city to the bush: Increases in patient co-payments for medicines have impacted on medicine use across Australia. Australian Health Review, 37, 4–10.10.1071/AH11129
- Kilic, B., & Maybarduk, P. (2012). Comparative analysis of the United States' Intellectual Property Proposal and Laws of New Zealand. Washington, DC: Public Citizen.
- Kirk, A. R. (2012). 2012 Special 301 Report, USA. Retrieved from http://www.ustr.gov/sites/default/files/2012%20Special%20301%20Report.pdf
- Kyle, M. K., & McGahan, A. M. (2009). Investments in pharmaceuticals before and after TRIPS. NBER Working Paper No. 15468. Cambridge, MA: National Bureau of Economic Research.
- Labonte, R., & Torgerson, R. (2005). Interrogating globalization, health and development: Towards a comprehensive framework for research, policy and political action. Critical Public Health, 15, 157–179.10.1080/09581590500186117
- Light, D. W. (2006). Basic research funds to discover important new drugs: Who contributes how much? In M. A. Burke & A. de Francisco (Eds.), Monitoring financial flows for health research 2005: Behind the global numbers (pp. 28–45). Geneva: Global Forum for Health Research.
- Lopert, R., & Gleeson, D. (2013). The high price of “free” trade: US trade agreements and access to medicines. Journal of Law, Medicine and Ethics, 41, 199–223.
- Lupton, D. (1992). Discourse analysis: A new methodology for understanding the ideologies of health and illness. Australian Journal of Public Health, 16, 145–150.
- Medecins Sans Frontieres. (2012). Trading away health: How the US’s intellectual property demands for the Trans-Pacific Partnership Agreement threaten access to medicines. MSF Access Campaign Issue Brief. Retrieved from http://www.msfaccess.org/sites/default/files/MSF_assets/Access/Docs/Access_Briefing_TPP_ENG_2012_update.pdf
- Ministry of Health. (2013). New Zealand Health Survey: Annual update of key findings 2012/13. Wellington: Ministry of Health.
- Moir, H., Tenni, B., Gleeson, D., & Lopert, R. (2014). Assessing the impact of alternative patent systems on the cost of health care: The TPPA and HIV treatment in Vietnam. Paper presented at the Asia-Pacific Innovation Conference, University of Technology, Sydney. Retrieved from http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2536254
- Monasterio, E., & Gleeson, D. (2014). The Trans Pacific Partnership Agreement: Exacerbation of inequality for patients with serious mental illness. Australian and New Zealand Journal of Psychiatry, 48, 1077–1080.10.1177/0004867414557679
- Nguyen, A. T., Knight, R., Mant, A., Cao, Q. M., & Auton, M. (2009). Medicine prices, availability, and affordability in Vietnam. Southern Med Review, 2, 2–9.
- Outterson, K., & Smith, R. (2006). Counterfeit drugs: The good, the bad and the ugly. Albany Law Journal of Science and Technology, 16, 525–543.
- Oxfam America. (2011). Oxfam America analysis of the USTR Trade Enhancing Access to Medicines (TEAM) white paper. Retrieved from http://www.citizen.org/documents/Oxfam-America-Analysis-of-USTR-TEAM-White-Paper.pdf
- Palmedo, M. (2013). Do pharmaceutical firms invest more heavily in countries with data exclusivity? Currents International Trade Law Journal.
- PHARMAC. (2013a). Pharmaceutical Management Agency annual report for the year ended 30 June 2013. In PHARMAC (Ed.), Wellington: Pharmaceutical Management Agency. Retrieved March 2015, from https://www.pharmac.health.nz/assets/annual-report-2012-2013.pdf
- PHARMAC. (2013b). Purchasing medicines (Pamphlet). Retrieved 20 June, 2014, from http://www.pharmac.health.nz/assets/infosheet-05-purchasing-medicines-2013.pdf
- Pharmaceutical Research and Manufacturers of America (2009). PhRMA written comments concerning the proposed Trans-Pacific Partnership Free Trade Agreement with Singapore, Chile, New Zealand, Brunei Darussalam, Australia, Peru and Vietnam. Retrieved March 2013, from www.regulations.gov
- Program on Information Justice and Intellectual Property (n.d.). IP enforcement database: The revolving door [Webpage]. Retrieved August 17, 2013, from https://sites.google.com/site/iipenforcement/the-revolving-door
- Ragupathy, R., Aaltonen, K., Tordoff, J., Norris, P., & Reith, D. (2012). A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand. Pharmaco Economics, 30, 1051–1065.
- Régnier, S. (2013). What is the value of ‘me-too’ drugs? Health Care Management Science, 16, 300–313.10.1007/s10729-013-9225-3
- Researched Medicines Industry Association of New Zealand Incorporated. (2008). Trans Pacific Strategic Economic Partnership Agreement: Submission to Ministry of Foreign Affairs and Trade from the Researched Medicines Industry Association of New Zealand Incorporated. Retrieved March, 2013, from http://mfat.govt.nz/Trade-and-Economic-Relations/2-Trade-Relationships-and-Agreements/Trans-Pacific/index.php
- Schrecker, T. (2014). Globalization, austerity and health equity politics: Taming the inequality machine, and why it matters. Critical Public Health, doi:10.1080/09581596.2014.973019
- Searles, A., Doran, E., Faunce, T. A., & Henry, D. (2013). The affordability of prescription medicines in Australia: Are copayments and safety net thresholds too high? Australian Health Review, 37, 32–40.10.1071/AH11153
- Sell, S. K. (2007). TRIPS-plus free trade agreements and access to medicines. Liverpool Law Review, 28, 41–75.10.1007/s10991-007-9011-8
- Sell, S. K., Fattahi, P., & Palmedo, M. (2011). Chapter 2: Networked governance and the USTR. In J. Karaganis (Ed.), Media piracy in emerging economies (pp. 75–98). Brooklyn, NY: Social Science Research Council.
- Smith, R. D., Correa, C. M., & Oh, C. (2009). Trade, TRIPS, and pharmaceuticals. The Lancet, 373, 684–691.10.1016/S0140-6736(08)61779-1
- Trans Pacific Partnership. (2011a). Intellectual property rights chapter (selected provisions). Retrieved September 2011, from http://www.citizenstrade.org/ctc/wp-content/uploads/2011/10/TransPacificIP1.pdf
- Trans Pacific Partnership. (2011b). Intellectual property rights chapter draft. Retrieved February 10, 2011, from http://keionline.org/sites/default/files/tpp-10feb2011-us-text-ipr-chapter.pdf
- Trans Pacific Partnership. (2011c). Transparency chapter – Annex on Transparency and Procedural Fairness for Healthcare Technologies, June 22, 2011. Retrieved 17 August 2013, from http://www.citizenstrade.org/ctc/wp-content/uploads/2011/10/TransPacificTransparency.pdf
- Trans Pacific Partnership. (2013). Intellectual property [Rights] chapter – Consolidated text. [Leaked draft text]. Wikileaks Release, November 13, 2013. Retrieved 24 November 2013, from http://wikileaks.org/tpp/static/pdf/Wikileaks-secret-TPP-treaty-IP-chapter.pdf
- Trans Pacific Partnership. (2014). Intellectual property [Rights] chapter - Consolidated text. Ho Chi Minh Round - May 16, 2014 [Leaked draft text]. Retrieved March, 2015 from https://wikileaks.org/tpp-ip2/
- UNAIDS. (2013). UNAIDS report on the global AIDS epidemic 2013. Retrieved from http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf
- van Dijk, T. A. (1993). Principles of critical discourse analysis. Discourse & Society, 4, 249–283.
- Wikipedia. (2014). Level playing field. Retrieved January 26, 2014, from http://en.wikipedia.org/wiki/Level_playing_field
- World Health Organization. (2001). How to develop and implement a national drug policy. Retrieved from http://apps.who.int/medicinedocs/pdf/s2283e/s2283e.pdf